All.Can: changing cancer care together
Presented by: Eduardo Pisani (CEO All.Can international)
All.Can is multi-stakeholder not-for-profit organization working to improve the efficiency of cancer care by focusing on what matters to patients. In this spirit, they bring together healthcare professionals, representatives from patient organizations, policymakers, researchers, and the pharmaceutical industry. Anno 2023, All.Can is active in 24 countries, including many European countries, Australia, Argentina, Colombia, Canada, Japan, South Korea, etc. Across these different countries, All.Can tries to work in a spirit of collaboration with the aim to have as much impact as possible. To this end, All.Can is always looking for a mandate to help with the aim of creating value for patients and for the healthcare system. The latter is amply illustrated by the fact that All.Can has been approached by the Organization for Economic Co-operation and Development (OECD) to help in drafting up their cancer report. Similar things are also happening on a regional level. For example, All.Can Australia is currently involved in the development of the country’s cancer related policy.
Increasing the efficiency of cancer care has always been the mantra for All.Can. For example, in 2022 they published an efficiency metrics study, proposing a set of internationally applicable, real-world measures that were generated and collected from daily clinical practice. The report, developed in collaboration with the university of Southampton, identified 8 core efficiency metrics that can be used by stakeholders to assess and improve cancer care efficiency. In a next step, All.Can together with the Amsterdam Medical Center (AMC) will look at ways to implement these metrics in different healthcare systems. Another way to improve efficiency is showcasing good practices. In this light, All.Can has created an ‘efficiency hub’ collecting different examples of best practices in cancer care from around the world. This creates a learning platform around efficient practices which could help organizations to find and implement potential solutions for common issues.
On a final note, Mr. Pisani underscored that there has never been more momentum to rethink cancer care than now. In fact, the European Union has recently launched its cancer plan, providing a framework for projects that aim at improving the care for cancer patients. While
this cancer plan offers an excellent platform for new projects, it also comes with the risk for dilution and fragmentation of projects. To improve the potential impact of these projects it seems wiser to bring experts and resources together and set up projects in a more coordinated way. And that is exactly what All.Can is all about.
All.Can Belgium: a state of affairs and future plans
Presented by An Cloet (MSD Belgium & Luxembourg)
All.Can Belgium is a multistakeholder platform that was launched in 2018 with the aim to align the different stakeholders on a joint vision on cancer care. To this end, All.Can Belgium initiates projects that deliver this vision and proposes solutions that contribute to a more efficient and innovative cancer care across the patient pathway. Furthermore, All.Can Belgium proactively provides input into the policy debate and wants to create societal support for their vision on cancer care. In 2022, the main activities of All.Can Belgium consisted of the OPTIMOC study (discussed later), a webinar on survivorship and the launch of the JUVENTAS project. The aim of JUVENTAS is to create awareness among adolescents and young adults on the early signs of breast cancer, testicular cancer, and sarcoma. In addition to an awareness campaign in schools and in the media, this project also includes surveys looking into the cancer knowledge of adolescents and assessing the obstacles they encounter in discussing potential early signs of cancer with their physician. In 2023, All.Can Belgium will continue to focus on OPTIMOC and JUVENTAS. In addition to this, a memorandum discussing the priorities for cancer care in the next 4 years is being prepared and All.Can Belgium is also looking into ways to improve the efficiency of clinical trials. Finally, 2023 also features the launch of the lung cancer working group of All.Can Belgium, with plans for a round table debate on lung cancer screening and a number of initiatives during the lung cancer awareness month in November.